



# Promega – Your dedicated Life Science partner!

Lyon Biotuesdays

March 5, 2024



**Jennifer Serriere-Di Bartolo**

Biopharma Strategic Collaboration & Marketing Manager, Ph.D.

[jennifer.serriere@promega.com](mailto:jennifer.serriere@promega.com)

Mobile: +33 6 14 68 66 29

Office: +33 4 37 22 50 00


[Connect on LinkedIn](#)



# Promega, a global player in Life sciences

## Promega Corporation

- Promega Headquarter located in Madison
- Independant company
- R&D driven business model
- + 2,400 employees in 16 countries





 **William A. Linton,  
Chairman & CEO**



## Promega France

- Founded in 1992 (50 people)
- Located in Charbonnières-Les-Bains
- SAT European Training and Application Lab
- On-site customer service & technical support

# Innovative Technologies Developer



## Promega Today

**700M+**

in revenue (U.S. Dollar)

**16,700+**

Citations in 2023

[Google scholar](#)

**Over  
2,400**

Employees

**500+**

active patents

**+250**

R&D scientists

**25+**

Scientific papers  
per year

**20+**

Worldwide congresses  
Covered in 2023  
(R&D talk)


**>85%**

Of products are  
Manufactured  
in-house

Sold in  
**100+**  
countries

Discovering  
a better world,  
*together*

# Value Chain for Small-molecule, Biologics, ATMP and Vaccine Drug Discovery





# Based on numerous Scientific & Industrial collaborations!

## With KOLs

(e.g. Shokat on RAS onco,  
Stanford for neuro)

[nature chemical biology](#)

Explore content ▾ About the journal ▾ Publish with us ▾

Article | Open access | Published: 21 March 2022  
KRAS is vulnerable to reversible switch-II pocket engagement in cells

James D. Wang, D. Matthew Peacock, Gelingh Zheng, Joel A. Walker, Ziqiang Zhang, Chad A. Zimmerman, Michael J. Beck, Brock T. Binkowski, Caesar K. Correia, Matthew B. Roberts, N. Keegan, M. Shokat

30K Accesses | 38 Citations | 113 Altmetric | Metrics

[nature chemical biology](#)

Explore content ▾ About the journal ▾ Publish with us ▾

nature | nature chemical biology | articles | article  
nature | Open access | Published: 21 March 2022  
An optimized bioluminescent substrate for non-invasive imaging in the brain

Vichit Su, Joel A. Walker, May J. Hall, Mark A. Stein, Xiang Wu, Lance P. Encoll, Serafin M. Casey, Lan Xiang, Liu Guoping, Hong, Michael J. Lin, & Thomas A. Kirkland

Nature Chemical Biology | 19: 731–739 (2023) | [Cite this article](#)

10K Accesses | 11 Citations | 131 Altmetric | Metrics

[Stanford MEDICINE](#)

Bioluminescence imaging (BLI) allows non-invasive visualization of cells and biochemical events in living organisms, including humans, with high sensitivity and resolution. However, BLI in the central nervous system remains challenging because it suffers from low relative poor performance in the brain with existing substrates. Here, we report the discovery of a Novel *in vitro* substrate with improved brain performance, cophalorufimazine (CFz). CFz paired with Antares luciferase produces greater than 20-fold more signal from the brain than the standard combination of *luciferin* and firefly luciferase. At standard doses, Antares CFz matches Alakaluc - Alakalume/TokeOn in brightness, while occasional higher dosing of CFz can be performed to obtain threefold more signal. CFz should allow the

## With Pharmas

(e.g. Amgen or AZN on PROTACs)

[NIH National Library of Medicine](#)

PubMed®

AMGEN

Search

Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs

Han Bai, ..., Alvin M. Hwang, ..., Jason Meier, ..., Han Wu, ..., Yuxing Li, ..., Shu-Cheng Li, ..., Ming Tang, ..., Mingming Li, ..., Daniel J. D'Amato, ..., Margherita Urti, ..., Brodsky-Bach, ..., Sami C. Humpf, ...

Affiliations – colleagues

[nature chemical biology](#)

Explore content ▾ About the journal ▾ Publish with us ▾

nature | nature chemical biology | articles | article  
nature | Open access | Published: 14 August 2023  
Simultaneous inhibition of DNA-PK and Polo improves integration efficiency and precision of genome editing

Sandra Wimbacher, ..., Niina Almela, ..., Mike Firth, ..., John Kengnani, ..., Susanne Engberg, ..., Maria K. Schwinn, ..., Michael B. Steller, ..., Andrei Luchin, ..., Pei-Jie Huang, ..., Songqian Li, ..., Silvia Cebrian, ..., Jonathan Sumner, ..., Karsten, ..., Basilio Schiffler, ..., Béatrice Magnusson, ..., Silvio Di Castro, ..., Freed, ..., Mohammad Boffi, ..., V. Thomas Macchidi, ..., Steve Hess, ..., Olga Engleki, ..., Tyrell Norris, ..., Bairie B. Cadogan, ..., Josep V. Ferrer, ..., Maurolo Messia

11K Accesses | 4 Citations | 79 Altmetric | Metrics

[AstraZeneca](#)

Abstract

Genetic screens of target, limit, break, identify genes

Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®

MERCK

Madison, WI USA, (November 6, 2019)  
Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega's microsatellite instability (MSI) technology as an on-label, solid tumor companion diagnostic (CDx) for use with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab). The global collaboration will initially seek regulatory approval for the Promega MSI CDx in the United States and China. Plans to seek approvals in additional territories may follow.

"It is gratifying to see our MSI technology have such meaning within the oncology community."

## With Regulatory Authorities

(e.g. FDA on AAV Gene Tx)

[nature biomedical engineering](#)

Explore content ▾ About the journal ▾ Publish with us ▾

Article | Published: 22 November 2022  
Rational immunosignaling of a promiscuous T-cell epitope in the capsid of an adeno-associated virus

Yan Bai, ..., Alvin M. Hwang, ..., Jason Meier, ..., Han Wu, ..., Yuxing Li, ..., Shu-Cheng Li, ..., Ming Tang, ..., Mingming Li, ..., Daniel J. D'Amato, ..., Margherita Urti, ..., Brodsky-Bach, ..., Sami C. Humpf, ...

FDA

[nature communications](#)

Explore content ▾ About the journal ▾ Publish with us ▾

nature | nature communications | articles | article  
nature | Open access | Published: 14 August 2023  
Designing immunogenicity of Adeno-associated viruses (AAVs) gene therapies using AAVs containing promiscuous epitopes. Thus, by engineering one viral capsid, the mediation of epitope binding to major histocompatibility complex class I alleles, sequence conservation analysis in AAV prophage and site-directed mutagenesis, we developed a strategy to generate a single AAV vector that can be used to express multiple epitopes. Test expression of AAVs with AAVs sequence ubiquitous to the immune system while preserving its functions, potency, cellular specificity, transduction efficacy and distribution. This rational approach to the immunodominance of capsid epitopes promises fast licensing of AAVs may be applicable to

## With Global CROs

(e.g. Wuxi on TE HT screening)

[Cell Chemical Biology](#)

DEIs enable the development of BRET probes for target engagement studies in cells

Resource

Graphical abstract

Authors

Kyle A. Teske, Wenzh Si, Cesare P. Corrao, ..., Michael J. Hwang, ..., Christopher J. Lovell-Kiss, ..., Matthew B. Roberts

Correspondence

Ibtis, Jauhali@wuxiapp.com (I.J.), mrob@wuxiapp.com (M.B.R.)

In brief

Teske et al. demonstrate the conversion of a deoxyribozyme (DEI) into a functional cellular target engagement probe. DEIs are unique enzymes that can be programmed to bind to specific targets and then catalyze the protonation of one perylene diimide (PDI) molecule. This allows for the generation of a PDIs-based probe designed for diverse target classes.

[WuXi AppTec](#)

**FUJIFILM**

**Cellular Dynamics**

**INOVIQ**

**AstraZeneca**

**GSK**

**AXXAM**

**Swiss TPH**  
Swiss Tropical and Public Health Institute

**BASF**

Strategic collaboration to advance novel assay development for drug discovery (iPSCs)

Partnership to support biomarker discovery and diagnostics development

Collaboration to develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit

Collaboration for creating advanced assays for early-stage drug discovery

Collaboration for innovative research for malaria control (PROTACs)

## Strong values based on Science, Art & Human in a Sustainable Environment



Promega

- PRIMARY MANUFACTURER**
- cGMP Manufacturing**
- 15 ISO CERTIFIED Locations**
- ISO 13485 & 9001**




Thank You!  
**How Can We Help?**



## Une démarche environnementale Globale

- **100% d'électricité renouvelable** d'ici 2025
- Installations **éco-responsable** (panneaux solaires, géothermie, recyclage de l'eau, constructions à double peaux,...)
- Produits respectueux de l'environnement utilisant **moins d'emballages**, moins de composants dangereux et générant **moins de déchets**.
- **Envois à température ambiante** ~~glace-carbonique~~ → **réduire les émissions de carbone** (en évitant les emballages en polystyrène).
- Helix® Programme de stockage sur site : regrouper les expéditions + **réduire les emballages**.



## Une démarche environnementale forte au sein de Promega France



- Certification ISO 14001 : 2015 depuis décembre 2022
- Production de l'électricité couvrant 30 % de nos besoins grâce à nos 50 panneaux solaires depuis 2021
- 100 % de voitures électriques ou Hybrides depuis 2022 et mise en place du covoiturage depuis 2021
- Mise en place de 3 bornes électriques (6 recharges possibles en //) depuis 2021
- Recyclage (papiers et emballages) à hauteur de 3,2 tonnes/an
- Notre « Bees team » gère nos ruches depuis 2017 avec le support d'un apiculteur (30 à 40 kg de miel/an)
- Participation à l'activité « Clean in Lyon » en 2023
- Adhérent depuis 2022 à l'Entreprise des Possibles et participation à différentes actions humanitaires
- Pour en savoir plus : [promega.com/responsibility](https://promega.com/responsibility)

